Cervical Cancer
Conditions
Brief summary
the main purpose for this experiments are as follows: 1. Patients with stage ⅡB-ⅢB cervical squamous cell carcinoma who received full dose radiotherapy will be randomly assigned to the combined TP regimen weekly treatment group and 3-week treatment group for the short-term efficacy and safety observation; 2. All enrolled patients will be tested for HPV subtype infection; the relationship between the sensitivity and curative effect of concurrent radiotherapy and chemotherapy will be analyzed, and at the end of the test, HPV subtypes will be tested again and changes will be analyzed to provide more clinical evidence for the reasonable comprehensive treatment and precision medical treatment of advanced cervical squamous cell carcinoma.
Interventions
PROCEDUREThe concurrent 3 weeks TP regimen
paclitaxel + cisplatin regimen (TP-TAX: 150mg/m\^2, DDP: 70mg/m\^2 (35mg/m\^2, d1, d2), 1 time/3 weeks) chemotherapy for 2 cycles.
PROCEDUREThe concurrent weekly TP regimen
paclitaxel + cisplatin regimen (TP regimen: TAX 50mg/m\^2, DDP: 25mg/m\^2) 6 cycles of chemotherapy
RADIATIONExternal radiation plus intraluminal after-loading irradiation
External radiotherapy of linear accelerator, CT simulation positioning, and intensity modulated radiotherapy will be applied for external radiotherapy. The prescribed dose is 95% PTV 45-50.8Gy/25-28 times (1.8Gy/time), the maximum and minimum in the target area do not exceed ±10% of the prescribed dose, and the increase in enlarged lymph nodes will reach 50-66GY. At the same time, the total dose of 192Ir high-dose rate intraluminal after-loading irradiation is 30-36Gy (EQD2: 40-48GY), and external pelvic irradiation is not available on the day of intraluminal after-loading irradiation.
Sponsors
Chongqing University Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. The patient participated in this study voluntarily and all volunteers will sign the informed consent. 2. New cervical squamous cell carcinoma cases between 18 and 70 years old; 3. Clinical stages: stage ⅡB-stage ⅢB; 4. PS score is less than 2 points; 5. Expected survival is over 3 months; 6. Blood routine: Hb≥70g/L, WBC≥3.5×10\^9/L, ANC≥1.5×10\^9/L, PLT≥80×10\^9/L 7. Serum ALT and AST≤2×ULN; serum creatinine≤1.5×ULN; 8. Women of childbearing age must undergo a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and are willing to use appropriate methods of contraception during the trial; 9. Patients who can comply with the trial protocol (judged by the investigator).
Exclusion criteria
1. Active or uncontrolled serious infection; 2. Liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis require antiviral treatments; 3. A history of immunodeficiency, including HIV positive or other acquired congenital immunodeficiency diseases; 4. Chronic renal insufficiency and renal failure; 5. Pregnant woman; 6. Myocardial infarction, severe arrhythmia and congestive heart failure ≥2 (New York Heart Association (NYHA) classification); 7. Patients receiving targeted therapy and pelvic artery embolism; 8. Those who have had arterial/venous thrombosis within 6 months, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism; 9. Those who have received radiotherapy for malignant pelvic tumors in the past; 10. Patients with autoimmune system diseases such as systemic lupus erythematosus; 11. Patients with comorbidities who need to take drugs with severe liver and kidney damage during treatment, such as tuberculosis; 12. Patients who cannot understand the content of the experiment and cannot cooperate, and those who refuse to sign the informed consent; 13. Those with concomitant diseases or other special circumstances that seriously endanger the safety of patients or affect the completion of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| disease control rate (DCR) | 1 month and 3 months | Including the percentage of patients with complete remission, partial remission or with stable disease state and maintained for more than 4 weeks among the patients with evaluable efficacy. |
| Objective response rate (ORR) | 1 month and 3 months | Including the percentage of patients with complete remission or partial remission and maintained for more than 4 weeks among the patients with evaluable efficacy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival (PFS) | 2 years | the time from patient randomization to objective progression or death. |
| overall survival (OS) | 3 years | the time from the beginning of enrollment to death for any reason. For subjects who are lost to follow-up, the time of last follow-up is usually calculated as the time of death. |
Countries
China
Outcome results
None listed